Clin2
NCT07174843Possibly a fitRecruiting

CAR-T cell therapy for autoimmune diseases

Idiopathic Inflammatory Myopathies(IIM)Immune Thrombocytopenia(ITP)Systemic Lupus Erythematosus(SLE)

Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.

This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
20 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are between 18 and 70 years old
  • Your autoimmune disease (like lupus, myositis, or ITP) has come back or not improved after standard treatments
  • Your blood counts and organ function (kidney, liver, lungs) are within acceptable ranges
  • You have not had certain infections (like HIV, hepatitis B/C, or active tuberculosis)
  • You do not have a history of severe heart disease or certain cancers

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06249438Recruiting· Phase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases

This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.

Shanghai, Shanghai Municipality
NCT07544225Not yet recruiting· Phase 1
CAR-T cell therapy for severe autoimmune rheumatic diseases

This trial tests a new treatment called CAR-T cell therapy for people with severe autoimmune rheumatic diseases that have not improved with other treatments. The therapy uses your own immune cells, which are modified in a lab to attack the cells causing the disease, potentially reducing symptoms and improving quality of life.

Villejuif, Val de Marne
NCT06420154Not yet recruiting· Early Phase 1
CAR-T cell therapy for severe autoimmune diseases

This trial is testing whether a type of immune cell therapy called CAR-T cells can help people with severe autoimmune diseases that have not improved with standard treatments. It may offer a new option for conditions like lupus, Sjogren's syndrome, or vasculitis when other therapies have failed.

Wenzhou, Zhejiang
NCT07246096Recruiting· Early Phase 1
CAR-T cell therapy for autoimmune diseases

This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.

Shanghai
NCT07586267Recruiting· Early Phase 1
CAR-T cell therapy for autoimmune blood diseases

This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.

Hangzhou, Zhejiang
NCT06279923Recruiting· Early Phase 1
CAR-T cells for autoimmune diseases

This trial tests a new CAR-T cell therapy that targets two immune proteins (CD19 and BAFF) to treat autoimmune diseases like lupus or scleroderma. It is for people who have not improved with standard treatments.

Hangzhou, Zhejiang

Hear when a new Immune Thrombocytopenia (ITP) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.